News Release 

Researchers explore link between 'Alzheimer's gene' and COVID-19

City of Hope

Research News

A City of Hope-led research team found that the same gene that increases the risk for Alzheimer's disease, ApoE4, can increase the susceptibility to and severity of COVID-19.

"Our study provides a causal link between the Alzheimer's disease risk factor ApoE4 and COVID-19 and explains why some (e.g., ApoE4 carriers) but not all COVID-19 patients exhibit neurological manifestations" said Yanhong Shi, Ph.D., director of the Division of Stem Cell Biology at City of Hope and co-corresponding author of the new study. "Understanding how risk factors for neurodegenerative diseases impact COVID-19 susceptibility and severity will help us to better cope with COVID-19 and its potential long-term effects in different patient populations."

At the beginning of the study, the team was interested in SARS-CoV-2's effects on the brain. Due to the fact that COVID-19 patients often lose their sense of taste and smell, the team theorized that the virus had an underlying neurological effect.

The team first created brain cells in the lab using pluripotent stem cells (iPSCs), which are a kind of stem cell that can become virtually any type of cell. The newly created neurons and astrocytes, a type of helper cell, were then infected with SARS-CoV-2. They found that both cell types were susceptible to infection.

Next, the team used iPSCs to create brain organoids, which are 3D tissue models that mimic certain features of the human brain. They created one organiod model that contained astrocytes and one without them. They infected both brain organoid types with the virus, and discovered that those with astrocytes boosted SARS-CoV-2 infection.

The team went on to further study the effects of ApoE4 on susceptibility to SARS-CoV-2. They did this by generating neurons from iPSCs "reprogrammed" from the cells of an Alzheimer's patient that contained ApoE4. Using gene editing, the team modified some of the iPSCs-created ApoE4 cells so that they contained ApoE3, which is a gene type that is considered neutral. The ApoE3 and ApoE4 iPSCs were then used to generate neurons and astrocytes.

The results were published recently in the journal Cell Stem Cell. The ApoE4 neurons and astrocytes both showed a higher susceptibility to SARS-CoV-2 infection in comparison to the neutral ApoE3 neurons and astrocytes. Moreover, while the virus caused damage to both ApoE3 and ApoE4 neurons, it appeared to have a slightly more severe effect on ApoE4 neurons and a much more severe effect on ApoE4 astrocytes compared to ApoE3 neurons and astrocytes.

In the last part of the study, the researchers tested to see if the antiviral drug remdesivir inhibits virus infection in neurons and astrocytes. They discovered that the drug was able to successfully reduce the viral level in astrocytes and prevent cell death. It was also able to rescue neurons from neurodegeneration.

The team's next step is to continue studying the effects of the virus to better understand the role of ApoE4 in the neurological manifestations of COVID-19. Many people infected with COVID-19 have recovered, but long-term neurological effects such as severe headaches are still seen months after.

"COVID-19 is a complex disease, and we are beginning to understand the risk factors involved in the manifestation of the severe form of the disease" said Vaithilingaraja Arumugaswami, Ph.D., a member of the UCLA Broad Stem Cell Research Center and co-corresponding author. "Our cell-based study provides a possible explanation as to why individuals with Alzheimer's' disease are at increased risk of developing more severe COVID-19 symptoms."

###

The research was supported by the Louise and Herbert Horvitz Charitable Foundation, the Sidell Kagan Foundation, California Institute for Regenerative Medicine (TRAN1-08525, DISC2 12172), the National Institute of Aging of the National Institutes of Health (R01 AG056305, RF1 AG061794, R56 AG061171), and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R21AI129471).

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope's translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHopeTM, a wholly owned subsidiary, was launched in 2019 and is dedicated to serving employers and their health care partners by providing access to City of Hope's exceptional cancer expertise. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation's "Best Hospitals" in cancer by U.S. News & World Report. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.